Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334979 | 0.99 | KDM4E (0.58) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL14520832 | 0.89 | KDM4E (0.58) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5333035 | 0.88 | KDM4E (0.57) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5334983 | 0.87 | KDM4E (0.58) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL14520803 | 0.85 | KDM4E (0.54) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5332966 | 0.84 | KDM4E (0.39) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL14520790 | 0.84 | HSD17B10 (0.55) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5451271 | 0.83 | KDM4E (0.40) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL207842 | 0.80 | KDM4E (0.73) | KDM4EUSP2ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5421106 | 0.80 | KCNA5 (0.52) | SMN1; SMN2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088043-A1 | Novel HDAC inhibitors | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-04-19 | — | — | US | claimed |
| WO-2007045962-A2 | NOVEL HDAC INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088043-A1 | Novel HDAC inhibitors | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088043-A1 | Novel HDAC inhibitors | HDAC1, HDAC11, HDAC5 | KDM4E 453/4885USP2 2376/4885ALOX15 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.